How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes.
Advances in the treatment of myelodysplastic syndromes (MDSs) over the last decade have given patients and their hematologists a multitude of treatment options. Therapeutic options now exist that reduce disease-related symptoms, improve quality of life, and alter the natural history of the disease. Three drugs are now specifically Food and Drug Administration-approved for treatment of MDS: (1) azacitidine, (2) decitabine, and (3) lenalidomide. Clinical results with each of these agents, plus results with immunosuppressive therapy, are reviewed to guide clinical decision making. Although each therapy has made a substantial impact in improving the care of patients with MDS, unfortunately MDS treatment in 2010 ultimately fails in most patients, but these therapies provide a foundation on which we can build to further improve outcomes.
Division of Hematology, Department of Medicine, The Ohio State University and Comprehensive Cancer Center, Columbus, OH 43210, USA. william.blum@osumc.edu
William
W
Blum
D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D017408:Guidelines as Topic; D006401:Hematologic Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D016896:Treatment Outcome
D006401:Hematologic Agents
Lancet Oncol. 2009 Mar;10(3):223-32
19230772
J Clin Oncol. 2008 Dec 20;26(36):5943-9
19018091
Ecancermedicalscience. 2008;2:118
22275990
Blood. 2010 Apr 1;115(13):2619-29
19965642
Hematol Oncol Clin North Am. 2010 Apr;24(2):389-406
20359633
J Clin Oncol. 2008 May 20;26(15):2505-11
18413642
Cancer. 2008 Oct 1;113(7):1596-604
18720364
Blood. 2007 Jan 1;109(1):52-7
16882708
Clin Cancer Res. 2008 Jul 15;14(14):4650-7
18628480
J Clin Oncol. 2009 Aug 10;27(23):3842-8
19528372
Blood. 2003 Mar 15;101(6):2156-8
12411290
J Clin Oncol. 2002 May 15;20(10):2429-40
12011120
N Engl J Med. 2005 Feb 10;352(6):549-57
15703420
Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11406-11
17576924
Blood. 2009 Mar 19;113(12):2867-8
19299654
Hematol Oncol Clin North Am. 2010 Apr;24(2):377-88
20359632
Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7473-8
20368434
Blood. 2009 Jan 29;113(5):1002-5
18824593
Best Pract Res Clin Haematol. 2007 Mar;20(1):49-55
17336254
Nature. 1974 Oct 4;251(5474):437-8
4421285
Cancer. 2006 Apr 15;106(8):1794-803
16532500
J Clin Oncol. 2006 Aug 20;24(24):3895-903
16921040
Br J Cancer. 2005 Sep 19;93(6):613-9
16222306
J Clin Pharmacol. 2005 May;45(5):597-602
15831784
Cancer. 2007 Mar 15;109(6):1133-7
17315156
N Engl J Med. 2006 Oct 5;355(14):1456-65
17021321
PLoS Med. 2008 Feb;5(2):e35
18271621
Blood. 2007 Aug 1;110(3):1080-2; author reply 1083
17644749
Semin Oncol. 2005 Aug;32(4 Suppl 5):S24-30
16085014
Blood. 2009 Nov 26;114(23):4847-58
19801443
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12974-9
19470455
Br J Haematol. 1997 Dec;99(3):699-705
9401087
Blood. 2008 Jan 1;111(1):86-93
17893227
Eur J Haematol. 2010 Aug;85(2):130-8
20394651
J Clin Oncol. 2009 Apr 10;27(11):1850-6
19255328
Future Oncol. 2005 Oct;1(5):575-83
16556034
Crit Rev Oncol Hematol. 2010 Dec;76(3):218-27
20451404
Nature. 2008 Jan 17;451(7176):335-9
18202658
Ann Intern Med. 2002 Aug 6;137(3):156-63
12160363
Blood. 2009 Apr 23;113(17):3947-52
18987358
Blood. 1975 Oct;46(4):519-33
1174689
Blood. 2000 Dec 1;96(12):3671-4
11090046
J Clin Invest. 2008 Jul;118(7):2427-37
18551193